LRRC37A

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, LRRC37A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LRRC37A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher LRRC37A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC37A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, ESCA, and UCEC are the cancer types where LRRC37A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BRCAOSMedianAll0.1150.578.00224view →
ESCAOSMedianAll0.0800.701<.00112view →
UCECDFSMedianAll1.0000.631.0472view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LRRC37A–BRCA (OS)

Kaplan–Meier survival curve for LRRC37A mutant vs wild-type samples in BRCA.

Open the BRCA breakdown →

Exploration